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Attenuating the Systemic Inflammatory Response to Adult
Cardiopulmonary Bypass: A Critical Review of the Evidence Base
R. Clive Landis, PhD;* Jeremiah R. Brown, PhD;† David Fitzgerald, CCP;‡
Donald S. Likosky, PhD;§ Linda Shore-Lesserson, MD, FASE;k
Robert A. Baker, PhD, CCP;¶ John W. Hammon, MD**
*Edmund Cohen Laboratory for Vascular Research, The University of the West Indies, Bridgetown, Barbados; †The Dartmouth Institute
for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire; ‡INOVA Heart and
Vascular Institute, Indiana OVA Fairfax Hospital for Children, Falls Church, Virginia; the §Department of Cardiac Surgery, University
of Michigan, Ann Arbor, Michigan; the kDepartment of Anesthesiology, Hofstra Northshore-LIJ Medical School, New Hyde Park,
New York; ¶Cardiac Surgery Research and Perfusion, Flinders University and Flinders Medical Centre, Adelaide, South Australia;
and the **Department of Cardiothoracic Surgery, Wake Forest University School of Medicine, Winston-Salem, North Carolina

Abstract: A wide range of pharmacological, surgical, and
mechanical pump approaches have been studied to attenuate
the systemic inflammatory response to cardiopulmonary bypass,
yet no systematically based review exists to cover the scope of
anti-inflammatory interventions deployed. We therefore conducted an evidence-based review to capture “self-identified”
anti-inflammatory interventions among adult cardiopulmonary
bypass procedures. To be included, trials had to measure at least
one inflammatory mediator and one clinical outcome, specified
in the “Outcomes 2010” consensus statement. Ninety-eight papers
satisfied inclusion criteria and formed the basis of the review. The
review identified 33 different interventions and approaches to
attenuate the systemic inflammatory response. However, only a
minority of papers (35 of 98 [35.7%]) demonstrated any clinical
improvement to one or more of the predefined outcome measures (most frequently myocardial protection or length of intensive care unit stay). No single intervention was supported by
strong level A evidence (multiple randomized controlled trials
[RCTs] or meta-analysis) for clinical benefit. Interventions at
level A evidence included off-pump surgery, minimized circuits,

biocompatible circuit coatings, leukocyte filtration, complement
C5 inhibition, preoperative aspirin, and corticosteroid prophylaxis. Interventions at level B evidence (single RCT) for minimizing inflammation included nitric oxide donors, C1 esterase
inhibition, neutrophil elastase inhibition, propofol, propionyl-Lcarnitine, and intensive insulin therapy. A secondary analysis
revealed that suppression of at least one inflammatory marker
was necessary but not sufficient to confer clinical benefit. The
most effective interventions were those that targeted multiple inflammatory pathways. These observations are consistent
with a “multiple hit” hypothesis, whereby clinically effective
suppression of the systemic inflammatory response requires hitting multiple inflammatory targets simultaneously. Further
research is warranted to evaluate if combinations of interventions
that target multiple inflammatory pathways are capable of synergistically reducing inflammation and improving outcomes after
cardiopulmonary bypass. Keywords: Inflammation, systemic–
CPB, inflammatory response, complications and management–
CPB, equipment, inflammatory inhibitors, outcomes. JECT.
2014;46:197–211

A systemic inflammatory response is triggered in
patients undergoing cardiothoracic surgery with cardio-

pulmonary bypass (CPB) as a result of the combination of
surgical trauma, activation of blood components in the
extracorporeal circuit, ischemia/reperfusion injury, and
endotoxin release (1–4). There is evidence for activation
of all the body’s major host defensive pathways, including
complement, coagulation, kinins, fibrinolysis, leukocytes,
platelets, and inflammatory cytokines (4–13). This broad
wave of systemic activation has been linked to adverse
clinical outcomes ranging from mild adverse effects (fever
or diffuse tissue edema), to moderate adverse effects
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(pathological hemodynamic instability or coagulopathy),
to severe complications (acute organ injury requiring
mechanical support), and even mortality (14–16).
A variety of approaches have been adopted in an
attempt to limit the systemic inflammatory response to
CPB. These include modifications to CPB equipment such
as filters to remove inflammatory leukocytes or soluble
mediators, minimized circuits to reduce surface area, coatings to improve the biocompatibility of extracorporeal
surfaces, or the elimination of CPB altogether with offpump coronary revascularization procedures. A range of
pharmaceutical interventions has also been investigated
such as steroidal and nonsteroidal anti-inflammatories,
complement inhibitors, protease inhibitors, antifibrinolytics, anesthetic regimens, antioxidants, and others. Previous evaluations of the evidence base have been limited
to meta-analyses or database reviews for a single intervention such as steroids or biocompatible surface coating, but
there has been no systematic evaluation of the literature
covering the complete range of anti-inflammatory strategies deployed.
The Society of Thoracic Surgeons (STS) Perfusion Guideline Writing Group is a multicountry, multi-institution
initiative tasked with producing evidence-based clinical
guidelines on a range of practices affecting outcomes in
CPB such as temperature management, renal protection,
blood conservation, and anti-inflammatory interventions.
An immediate challenge faced by the Inflammation Writing Group was the fact that a previous analysis of the
evidence base of pharmacological strategies to attenuate
the inflammatory response (17) had reported that only a
small minority of papers measured any traditional clinical
end points (e.g., death, myocardial infarction, stroke). The
problem is compounded by small sample sizes pervading
the inflammation literature (median sample size: n = 40)
(18), implying that there may not be adequate statistical
power to analyze hard clinical end points. A review process covering multiple peer reviews from cardiothoracic,
cardiac anesthesia, and perfusion journals as well as guideline writing committees of the STS, The Society of Cardiovascular Anesthesiologists, and The American Society of
Extracorporeal Technology eventually concluded that the
evidence base would be insufficient to recommend clinical
practice guidelines for anti-inflammatory interventions
based on traditional clinical end points.
The Inflammation Writing Group has therefore undertaken a critical review of the literature to illustrate the
scope of interventions and approaches being deployed in
the field to highlight promising areas of research and identify gaps in the literature. In this review, surrogate markers
of organ dysfunction and measures of hospital resource
use, defined in the “Outcomes 2010” consensus statement,
were accepted as outcomes (19), and studies had to “selfidentify” as being related to the systemic inflammatory
JECT. 2014;46:197–211

response. Finally, studies had to measure at least one
inflammatory marker using a relaxed definition of that
term to include markers of complement activation, coagulation, kinins, oxidative stress, endothelial activation,
white cell activation, white cell count, or a range of soluble
inflammatory mediators. These inclusion criteria yielded a
rich evidence base consisting of 98 papers covering a wide
range of interventions and approaches to reduce the
inflammatory response after adult CPB.
The purpose of this review was to identify gaps in the
literature, inform further research, and to critically evaluate the strength of the evidence base for practices capable
of attenuating the systematic inflammatory response and
their relationship to clinical outcomes.
MATERIALS AND METHODS
Literature Search
The literature search was designed to capture clinical
trials reporting on the inflammatory response to adult
CPB together with clinical outcomes or surrogate markers
for organ injury to five index organs: heart, lung, brain,
kidney, and gut. The search terms (Appendix A) recovered >1600 articles in PubMed.
Abstract and Paper Reviews
A title review narrowed the search to 602 abstracts that
were submitted for more detailed analysis using the
GuidelinerÔ reviewing software (www.Guideliner.org/default
.aspx, accessed September 15, 2014). All abstracts were
reviewed in duplicate by independent reviewers, of which
236 were selected for full paper review. To be included,
trials had to measure at least one clinical outcome and one
inflammatory mediator. The inclusion criteria were as follows: randomized clinical trial (RCT) or meta-analysis, adult
CPB, cardiac surgery, perioperative intervention, published
2002–2011, measured at least one inflammatory marker or
used an established anti-inflammatory strategy (e.g., steroid
or nonsteroidal anti-inflammatory drug), and measured at
least one prespecified clinical outcome (defined by “Outcomes 2010” Consensus Statement) (19). The rules for
deciding on inclusion/exclusion of papers were based on the
Methodology Manual and Policies From the American College of Cardiology Foundation/American Heart Association
(ACCF/AHA) Task Force on Practice Guideline (http://
assets.cardiosource.com/Methodology_Manual_for_ACC_
AHA_Writing_Committees.pdf); hence, any one reviewer
could select an abstract for inclusion in a full paper review,
but at least two reviewers had to agree to exclude a paper.
The same rules applied at the paper review stage with two
reviewers needing to agree whether to exclude a paper.
These rules were incorporated into GuidelinerÔ and the
following reviewers performed abstract and paper reviews:
R.C.L., J.R.B., D.S.L., and D.F. These same individuals
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decided on whether an intervention achieved a clinical benefit. The assessment of clinical benefit was derived from
review of each paper with regard to number of subjects
studied, quality of the biomarker data, clinical outcomes
achieved, and the strength of the statistical associations for
reduced inflammation and clinical outcomes. The assignment of Level of Evidence used ACC/AHA guidelines
(20). Any discordance between two reviewers was discussed
and resolved if necessary by an independent third reviewer
(J.H. and L.S.L.).

RESULTS
Synthesis of the Evidence Base
The literature search identified over 1600 papers, of
which 602 abstracts were selected based on title review
for entry into the GuidelinerÔ database. The GuidelinerÔ
reviewing software was used in all subsequent steps for
synthesizing the evidence base. Of 602 abstracts, 236 were
selected for full paper review (Figure 1). After verifying
inclusion/exclusion criteria 98 papers made up the final
evidence base (listed in the Appendix B). These covered
three broad categories of intervention: surgical and perioperative management (19 papers), perfusion-related
(35 papers), and pharmacological (44 papers). Thirty-five
of the 98 papers demonstrated a clinical benefit and were
distributed approximately evenly across the three categories (Table 1). The total number of patients forming the
evidence base was 17,676. The complete list of interventions and their associated level of evidence is summarized
in Table 2. An analysis of the most relevant interventions
according to the strength of evidence follows.
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Table 1. Summary of evidence base.
Category of Intervention

Number of Papers

Percentage with
Clinical Benefit (%)

Surgical/perioperative
management
Perfusion-related
Pharmacological
Total

19

6/19 = 31.6%

35
44
98

11/35 = 31.4%
18/44 = 40.9%
35/98 = 35.7%

Evidence Level A (multiple randomized controlled trials)
Off-Pump Surgery: There were 10 RCTs on off-pump
coronary revascularization surgery (Table 2). Four of the
10 papers demonstrated a clinical benefit. The studies
were not uniform, however, in that they differed with
respect to heparin dosing, and the control CPB groups differed with respect to circuit volume and use of cardioplegia.
There was considerable heterogeneity in the reporting of
inflammatory biomarkers with each of the 10 studies measuring a different set of markers that reflected inflammation. A best available summary of the evidence suggests
that the use of OPCAB may reduce myocardial injury
(troponin and CKMB), but this could not be linked in
an obligate relationship with inflammatory suppression.
Whereas the four studies with improved clinical outcome
did show inflammatory suppression, three other studies
with suppressed inflammation did not achieve a clinical
benefit. The median sample size for the OPCAB studies
was 50, reinforcing the thin evidence base even for this
relatively well studied intervention.
Minimized Extracorporeal Circulation: There were
eight RCTs on approaches to minimize the surface area of
the extracorporeal circuit, and three of these eight achieved

Figure 1. Synthesis of the evidence base. This illustration shows how the final 98 articles comprising the
evidence base were derived from the original search
strategy and what proportion achieved a clinical benefit.
GuidelinerÔ is a bespoke reviewing software specifically
purposed for this review process.
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Table 2. Summary of interventions and level of evidence.
Category of Intervention

Intervention

Surgical/perioperative
management

Off-pump coronary
revascularization
Preoperative aspirin
Preoperative fluvastatin
Left ventricular assist
Intensive insulin therapy
Continuous ventilation
No cardioplegic arrest
Minimized extracorporeal circuit
Biocompatible circuit coating
Leukocyte-depleting filter
Ultrafiltration
Pericardial blood processing
Discard mediastinal blood
Steroids
Complement inhibitors
C1 esterase inhibitors
Neutrophil elastase inhibitors
Nitric oxide donors
Propofol
Sevoflurane
Aminophylline
Propionyl-L-carnitine
Hydroxyethyl starch in prime
Gelatin colloid
Aprotinin
Adenosine
Ethyl pyruvate
Erythropoietin
Taurine
Glutamine
N-acetyl cysteine
Dual-dose tranexamic acid
Lidocaine

Perfusion-related

Pharmacological

Level of
Evidence
Level A
Level A
Level B
Level B
Level B
Level B
Level B
Level A
Level A
Level A
Level B
Level B
Level B
Level A
Level A
Level B
Level B
Level B
Level B
Level B
Level B
Level B
Level B
Level B
Level B
Level B
Level B
Level B
Level B
Level B
Level B
Level B
Level B

clinical benefit (Table 3). Again there was heterogeneity in
the range of inflammatory biomarkers studied and again
there was no clear linkage between suppression of inflammation and clinical outcome; hence, the three studies with
improved clinical outcome had suppressed inflammation,
yet three other studies with suppressed inflammation did
not show clinical improvement. The median sample size
for this intervention was 45.
Biocompatible Circuit Coating: There were 14 RCTs
examining different biocompatible surface coatings of
which six indicated a clinical benefit (Table 3). Heparin
was the most widely studied biocompatible coating plus
one paper was a direct comparison of two different types
of heparin-coated circuits. Poly-2-methoxyethylacrylate
and amphophilic silicone–caprolactone oligomer were also
studied as surface coatings. The same pattern between
inflammatory suppression and clinical outcome was
observed with 12 papers reporting inflammatory suppression but only six reporting a clinical benefit. Median sample size was 38.
Leukocyte-Depleting Filters: There were eight RCTs
studying leukocyte depletion, seven of which used the
JECT. 2014;46:197–211

same arterial line leuko-depleting filter. Two of these
eight studies were assigned a clinical benefit. Although
leukocyte numbers were diminished by leukofiltration,
inflammatory markers and leukocyte activation status
were increased. Median sample size for this intervention
was 36.
Corticosteroids: There were 13 RCTs and one Cochrane
database review (21) on steroid interventions. The
Cochrane meta-analysis was adequately powered (n =
3615) to study hard clinical end points and reported no
clinical benefit on mortality or myocardial and pulmonary
complications (21). Among the 13 RCTs, three were
assigned a clinical benefit (Table 4). Individual steroid
regimens showed a clinical benefit in only two of six studies of methylprednisolone, one of six studies of dexamethasone, and not at all in a hydrocortisone trial. The steroid
RCTs were relatively small (median n = 30) and lacked
uniformity with distinct steroid dosing regimens used in 12
of the 13 studies. The dissociation between inflammation
and clinical outcome was quite marked with all but one
study showing inflammatory suppression but only three
studies able to demonstrate a clinical benefit.
Complement Inhibitors: Five RCTs investigated the use
of complement inhibitors, three of which found a clinical
benefit. Differences were noted between different complement targets. The C1 esterase inhibitor studies were notable for their study design, using patients undergoing
emergency coronary artery bypass grafting (CABG) and
for the compelling myocardial protection observed despite
a modest sample size (median n = 66). The multicenter
PRIMO CABG trial for C5 inhibition missed its primary
composite end point of 30-day mortality/myocardial
infarction in patients undergoing CABG but was able to
demonstrate significant improvement in the highest risk
patient group for the combined PRIMO CABG I and II
studies (n = 7353 in total).
Aspirin: There was one RCT and one meta-analysis for
aspirin given preoperatively (Table 3), and neither study
was able to demonstrate a clinical benefit. The meta-analysis
for preoperative aspirin use (n = 824) was statistically
significantly associated with worsened reoperative rates.
Aspirin and clopidogrel given until surgery in combination
with aprotinin during surgery did not affect clinical outcome statistically, but there was concern about two deaths
in the treatment arm resulting from intestinal embolism in
this relatively small trial (n = 50).
Evidence Level B (single randomized controlled trial)
The full list of interventions at evidence level B is
included in Tables 3–5, but the most noteworthy interventions are discussed.

Berkan
(2009) [13]
Meyns
(2002) [14]
Stassano
(2009) [15]
Stassano
(2010) [16]
Zheng
(2010) [17]
Ng
(2009) [18]
Narayan
(2011) [19]

Rastan
(2005) [1]
Nesher
(2006) [2]
Serrano
(2009) [3]
Tsai
(2010) [4]
Sahlman
(2003) [5]
Wan
(2004) [6]
Velissaris
(2004) [7]
Quaniers
(2006) [8]
Paulitsch
(2009) [9]
Formica
(2009) [10]
Sun
(2008) [11]
Akowuah
(2005) [12]
Yes: IL-8, TNFa
No
Yes: C5b-9
No
No
N/D
Yes: platelet aggregation No

18
26
20
50
30
412
25

Yes: NE, C3
Yes: IL-6, TNFa,
CRP, NE
Yes: IL-6, IL-8, TNFa
Yes: IL-6, IL-10, TNFa
No
No

105
38

50
23
41

21

Yes: soluble P-selectin

23

25

6§

Yes: IL-8, CRP,
WBC, sP-selectin
Yes: IL-6, TNFa,
thrombomodulin
Yes; oxidative stress

40

No

No

Yes: ICU stay, cTnI

No

No

Yes: ICU stay,
cTnI, inotropes
No

No

No

No

No

No

No

No

Yes: ICU stay

Yes: CK-MB, cTnI

Yes: IL-6, IL-8

12

Comment

No improvement in myocardial injury, inotrope use,
or ICU stay in off-pump group; no benefit
Off-pump versus on-pump beating heart as control group;
no improvement in ICU stay or other clinical end points
No improvement in ICU stay or other clinical end points
off-pump
Two off-pump groups, receiving heparin at 1 or 3 mg/kg; no
change ICU stay or hard end points in either treatment group
No statistically significant changes in ICU stay or other hard
clinical end points in off-pump group
Comparison of off-pump with miniaturized extracorporeal
circuit; no change in myocardial protection or ICU stay
Preoperative aspirin is statistically significantly associated with
worsened reoperation rates (p <.02), at 325-mg dose
Aspirin and clopidogrel given preoperative, with perioperative
aprotinin; concern regarding two deaths resulting from
intestinal embolism
Fluvastatin (80 mg/day 3 weeks before surgery) significantly
improved ICU stay, TnI marker, and need for inotropes
CABG supported with intracardiac axial pump did not
improve any hard clinical endpoints or ICU stay
LVA (minus oxygenator or heat exchanger) compared to
MECC. No myocardial protection or other clinical benefit
LVA assisted beating heart surgery vs. conventional CPB.
No significant clinical changes
Insulin therapy (Portland Protocol) in patients with no history
of diabetes: improved ICU stay and TnI marker
Continuous ventilation throughout CPB had no effect on
bronchoalveolar lavage cell activation status or ICU stay
CPB without cardioplegic arrest did not alter myocardial injury
marker (TnI), neural marker (S100), or ICU stay

Significant myocardial protection off-pump (CK-MB and TnI)
but no improvement in other clinical end points
ICU stay and fever significantly improved off-pump

Yes: lactate, CK-MB Off-pump verus on-pump beating heart as control group;
CK-MB and lactate significantly improved by off-pump
Yes: CK-MB, cTnI
Significant myocardial protection (CK-MB and TnI) off-pump

Clinical Benefit
Yes–No:
Outcome Modified

60

194† Yes: CRP5‡

Author (year)
[reference]1* No.2†

‡

†

Number in square brackets [ ] refers to reference number in the Appendix B: “98 References Comprising the Evidence Base.”
N = number of subjects in treatment group.
Abbreviations used: RCT, randomized controlled trial; CABG, coronary artery bypass grafting; CRP, C-reactive protein; IL, interleukin; WBC, white blood cell count; TNF, tumor
necrosis factor; ICU, intensive care unit; NE, neutrophil elastase; C, complement; C5b-9, terminal complement complex; CK-MB, creatine kinase MB fraction; cTn, cardiac-specific
troponin; MECC, minimal extracorporeal circulation.
§
N/D, not done.

*

RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
Preoperative aspirin (1)
Meta-analysis
valve/CABG
Preoperative aspirin +
RCT,
clopidogrel, perioperative
CABG
aprotinin (1)
Preoperative fluvastatin (1) RCT,
CABG
Left ventricular assist (3)
RCT,
CABG
RCT,
CABG
RCT,
CABG
Intensive insulin therapy (1) RCT,
valve
Continuous ventilation (1)
RCT,
CABG
No cardioplegic arrest (1)
RCT,
CABG

Off-pump (n = 10)

Intervention (no. of papers)

Type of Study,
Surgery

Inflammatory
Biomarker(s)
Suppressed Yes–No:
Biomarker3‡

Table 3. Summary of surgical and perioperative management interventions.
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Minimized extracorporeal
circuit (8)

Amphophilic siliconecaprolactone oligomer (1)

Poly-2-methoxyethylacrylate (4)

Heparin head-to-head

Heparin coating (9)

Intervention (no. of papers)

Kofidis
(2008) [34]
Gunaydin
(2009) [35]
Rimpilainen
(2011) [36]
Tanaka
(2003) [37]

RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
valve

Ninomiya
(2003) [31]
Thiara
(2011) [32]
Allen
(2005) [33]

Baufreton
(2011) [28]
Hoel
(2004) [29]

RCT,
CABG
RCT, mixed
valve/CABG

RCT, mixed
valve/CABG
RCT,
CABG
RCT,
CABG

Mirow
(2011) [27]

RCT,
CABG

Skrabal
(2006) [30]

Baufreton
(2005) [25]
Vanden Eynden
(2008) [26]

RCT,
CABG
RCT, mixed
valve/CABG

RCT,
CABG

Lindholm
(2004) [24]

RCT, mixed
valve/CABG

Ueyama
(2004) [23]

De Vroege
(2004) [22]
Ueyama
(2004) [23]

RCT,
CABG
RCT, mixed
valve/CABG

RCT, mixed
valve/CABG

Heyer
(2002) [20]4*
Svenmarker
(2002) [21]

Author (year)
[reference]1*

RCT,
CABG
RCT,
CABG

Type of Study,
Surgery

Table 4. Summary of perfusion-related interventions.

9

Yes: IL-6, IL-8,
TNFa, NE, C3a
No

Yes: IL-6, C3a,
CD11b

20
18

Yes: IL-8

50

Yes: IL-10

No

15
20

Yes: C3a, NE

Yes: NE

Yes: ICU stay,
cerebral emboli
No

Yes: ventilator time,
cTnI
Yes: ICU, O2sat.
cerebral, CK-MB

No

No

No

Yes: neurocognitive
function

Yes: A-a O2 gradient

N/A

N/A7§
Yes: IL-6, CRP,
bradykinin

No

No

No

No

No

Yes: A-a O2 gradient

Yes: pulmonary shunt

Yes: neurologic
deviation

Yes: cognitive function

Clinical Benefit
Yes–No:
Outcome Modified

Yes: C5b-9

11

19

10

15

12

Yes: TAT

No

99
21

Yes: C5b-9

12

Yes: IL-8, NE,
C5b-9

Yes: IL-6, CRP,
bradykinin

10
21

Yes: C3b

Yes: WBC

Yes: C3a

6‡

26

256

26

5†

No.

2†

Inflammatory
Biomarker(S)
Suppressed Yes–No:
Biomarker3‡

Continued

Significantly improved cognitive dysfunction but
no other clinical changes; mild benefit
No difference in mortality, ventilator time or ICU
stay, but significantly less neurological deviation;
mild benefit
Decreased pulmonary vascular resistance and
pulmonary shunt; no other clinical changes
Two intervention groups: heparin and
poly-2-methoxyethyl acrylate (PMEA) coating;
both improved the A-a O2 gradient
No statistically significant change in ICU or
respirator time or inotrope support; no
myocardial protection (Tn T)
No statistically significant improvements in
prespecified neurological outcomes
No myocardial protection (CK-MB); no change
in ICU stay, intubation time, or other hard
clinical end points
No change in neurological lesions by diffusionweighted imaging; no change in ICU stay or
other clinical outcomes
No statistically significant differences between
groups in hard clinical end points
No control group in this heparin head-to-head trial;
no difference in inflammatory markers or
clinical outcomes
Two intervention groups: heparin and PMEA
coating; both improved the A-a O2
gradient significantly
Significant improvement in neurocognitive
function (Go/NoGo and Mini-Mental-test);
Nn change in ICU stay; mild benefit
No improvement in ICU stay or intubation time;
no clinical benefit
No benefit of PMEA over phosphorylcholine as
control; no difference in ICU stay
No difference between groups in creatinine, urea,
or N-acetyl glucosamine; no change in intubation
time or ICU stay
Improved myocardial protection (Tn I) and
ventilator time in minigroup
Significantly improved ICU stay, myocardial
protection (CK-MB), cerebral oxygen saturation,
and intubation time
Significantly decreased ICU time and microemboli
by retinal fluorography in minigroup
Closed cardiopulmonary bypass circuit does not
improve any prespecified clinical endpoints in
this small study

Comment
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Zhang
(2010) [44]
Hayashi
(2003) [45]
Chen
(2004) [46]
Koskenkari
(2006) [47]
Soo
(2010) [48]
Rubino
(2011) [49]
Tallman
(2002) [50]
Oliver
(2004) [51]
Torina
(2010) [52]
Marcheix
(2008) [53]

RCT,
valve
RCT,
valve
RCT, mixed
valve/CABG
RCT,
valve/CABG
RCT,
valve/CABG
RCT,
CABG
RCT,
CABG
RCT, mixed
valve/CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG

Pericardial blood
processing (1)

Discard mediastinal
blood (1)

Yes: IL-6,
thromboxane B2
Yes: IL-8, NE

25

17

Yes: IL-8, TNFa

No

No

20
25

No

No

No

No

Yes: IL-8, sP-sel.,
sICAM, ox. stress
No

Yes: NE,
oxidative stress

No

62

15

41

20

10

16

10

26

10

25

Yes: WBC,
oxidative burst
Yes: IL-6, C3a, CD11b

No

15

34

Yes: NE, C5b-9

101

No.9†

Inflammatory
Biomarker(S)
Suppressed Yes–No:
Biomarker10‡

No

No

No

No

No

No

No

No

No

No

No

Yes: CK-MB

Yes: A-a O2 gradient

No

No

No

No

Clinical Benefit
Yes–No:
Outcome Modified

Arterial line leuko-depleting filter; improved A-a
O2 gradient; no other clinical changes; mild benefit
Dual filter approach (continuous and after x-clamp)
provided significant myocardial protection
(CK-MB)
Arterial line filter improved myocardial protection
and respiratory index but increased
inflammatory cytokines
Cardioplegia leukocyte-depleting filter placed after
oxygenator reservoir did not change
clinical outcomes
Arterial line filter did not improve prespecified
clinical endpoints
Arterial line filter did not improve ICU stay or
clinical end points; neutrophil activation noted in
filter group
Arterial line filter did not improve ICU stay or
clinical end points; leukocyte activation noted in
filter group
Continuous arterial line plus cardioplegia filters did
not improve myocardial markers or ICU stay
Zero balance ultrafiltration; no change ventilator or
ICU time; paradoxical rise in plasma
inflammatory markers
Ultrafiltration; no clinical benefit in pulmonary
function or other prespecified outcomes
Modified ultrafiltration demonstrated no change in
A-a O2 gradient; no benefit
Blood processing with cell saving device did not
significantly improve ICU length of stay or other
hard clinical end points
Discarding mediastinal and cardiotomy suction
blood had no effect on adverse events or
myocardial marker (TnT)

No change in ICU duration or other clinical end
points in mini-group
No improvement in myocardial injury marker
(Tn T) in minigroup
No statistically significant improvements in ICU
stay or prespecified clinical end points
No change in any reported clinical outcomes

Comment

Number in square bracket refers to reference number in the Appendix B.
N, number of subjects in treatment group.
Abbreviations used: RCT, randomized controlled trial; CABG, coronary artery bypass grafting; WBC, white blood cell count; IL, interleukin; CRP, C-reactive protein; TNF, tumor
necrosis factor; NE, neutrophil elastase; TAT, thrombin antithrombin; sP-sel., soluble P-selectin; sICAM, soluble ICAM-1; A-a O2, arterial–alveolar oxygen gradient; CK-MB, creatine
kinase MB fraction; cTn, cardiac-specific troponin.
§
N/A, not appropriate.

‡

†

*

Ultrafiltration (3)

Leukocyte-depleting
filter (8)

Westerberg
(2004) [54]

Abdel-Rahman
(2005) [38]
Rex
(2006) [39]
Huybregts
(2007) [40]
Ohata
(2008) [41]
Alexiou
(2004) [42]
Gunaydin
(2009) [43]

RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG

Intervention (no. of papers)

Author (year)
[reference]8*

Type of Study,
Surgery
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Sodium
nitroprusside (1)

Complement receptor 1
inhibitor (1)
Neutrophil elastase
inhibitor (1)
Urinary protease
inhibitor (2)

Complement C5
inhibitor (2)

C1 esterase
inhibitor (2)

Cochrane review (1)

Hydrocortisone (1)

Dexamethasone (6)

RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT, mixed
valve/CABG
RCT,
CABG
RCT,
CABG
RCT, mixed
valve/CABG
meta-analysis
valve/CABG
RCT, emergency
CABG
RCT, emergency
CABG
RCT, mixed
valve/CABG
RCT, mixed
valve/CABG
RCT, mixed
valve/CABG
RCT,
valve
RCT,
CABG
RCT,
valve
RCT,
CABG

Methylprednisolone (6) RCT,
CABG

Intervention
(no. of papers)

Demir
(2009) [56]
Fillinger
(2002) [57]
McBride
(2004) [58]
Bourbon
(2004) [59]
Liakopoulos
(2007) [60]
Von Spiegel
(2004) [61]
Halvorsen
(2003) [62]
Loef
(2004) [63]
Yared
(2007) [64]
Sobiesky
(2008) [65]
Amr
(2009) [66]
Halonen
(2007) [67]
Dieleman
(2011) [68]
Thielmann
(2006) [69]
Fattouch
(2007) [70]
Verrier
(2004) [71]
Smith
(2011) [72]
Lazar
(2004) [73]
Fujii
(2010) [74]
Bingyang
(2007) [75]
Song
(2011) [76]
Gol
(2002) [77]

Giomarelli
(2003) [55]4*

Author (year)
[reference]1*

Table 5. Summary of pharmacological interventions.

Yes: IL-6, IL-10
Yes: IL-8, IL-10,
TNF
Yes: IL-6, TNF

15
18

147

10

24

15

6

72

2156

1378

38

28

1807

120

50

13

37

10

N/D

10
No

Yes: lung water

No

No

No

Yes: ICU stay,
NSE
No

Yes: CK-MB,
A-a O2 gradient

Clinical Benefit
Yes–No:
Outcome Modified

15 mg/kg bolus preoperatively; improved troponin (Tn) T but
worsened pulmonary shunt, hyperglycemia, and lactic acidosis
1 mg/kg after induction; improvement in lung water; mild benefit

10 mg/kg preoperatively; no clinical changes, no adverse events

1 g preoperatively, 5 + 125 mg postoperatively; improved myocardial
protection creatine kinase MB fraction (CK-MB)
and A-a O2 gradient
1 g before CPB; improved intensive care unit (ICU) length of stay
and levels of neuron specific enolase (NSE)
15 mg/kg preoperatively, 4 + .3 mg/kg postoperatively; less nausea
but no other changes in clinical outcomes
30 mg/kg before induction; no changes in clinical outcomes

Comment

Continued

4 mg perioperatively + 4 mg postoperatively; no change in hard
clinical end points, inotrope use, or reoperation rates
N/D
No
1 mg/kg at induction + .5 mg/kg postoperatively; significant glycosuria,
controlled through insulin; no clinical benefit
No
No
.6-mg/kg bolus; no clinical benefit and could not demonstrate
inflammatory suppression to a range of markers
Yes: IL-6
No
100-mg bolus after induction; no change A-a O2 gradient or
ICU stay; no clinical benefit
Yes: IL-6, IL-8
No
1 mg/kg at induction + .5 mg/kg postoperatively; significant
hyperglycemia; no change in hard end points; no benefit
Yes: CRP
No
100 mg days 1–4 of operation; no change to any prespecified
clinical end points
N/D
No
No beneficial effect of corticosteroid use on mortality, cardiac, and
pulmonary complications
Yes: C3, C4
Yes: cTnI
40-IU/kg bolus + 20 IU/kg infusion showed myocardial protection
(Trop. I) with earlier treatment from acute STEMI
Yes: C3a, C4
Yes: ICU stay,
1000 IU C1 INH provided convincing improvement in ICU length
cTnI
of stay and cardiac function (cTnI and wall motion)
Yes: serum
No
Multicenter trial; missed primary end point 30-day death/MI in
complement activity
CABG, but significant risk reduction in intent to treat analysis
Yes: serum
Yes: mortality
Analysis of combined PRIMO-CABG I and II trials; highest risk
complement activity
patients showed significant benefit at 30-day mortality
Yes: C3a, C5b-9
No
Striking gender bias; soluble CR1 significantly inhibited death/MI
in males but not females; overall no benefit
Infusion of neutrophil elastase inhibitor significantly improved
Yes: IL-6, IL-8, NE
Yes: PaO2/FiO2
ratio
PaO2/FiO2 ratio
Yes: IL-6, IL-8, NE,
Yes: ventilator time, Documented antiprotease activity is against neutrophil elastase;
improved ventilator time and A-a O2 gradient
TNFa
A-a O2 gradient
No
Yes: ICU stay
Infusion or urintary proteas inhibitor significantly improved
ICU stay; no change in inflammatory mediators
Yes: IL-6
Yes: ICU stay,
Na nitroprusside (NO donor) intravenously after x-clamp release;
inotropes
convincing improvement ICU stay and need for inotropes

Yes: IL-6, IL-18,
IL-10, TNF, CRP
N/D7§

40

12

Yes: IL-6, IL-10

Yes: IL-6, IL-8, IL-10,
TNFa6‡

15

10

5†

No.

2†

Inflammatory
Biomarker(S)
Suppressed Yes–No:
Biomarker3‡
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RCT,
valve
RCT,
valve
RCT, mixed
valve/CABG
RCT,
CABG
RCT, mixed
valve/CABG
RCT,
CABG
RCT,
CABG
RCT,
CABG
RCT, mixed
valve/CABG
RCT, mixed
valve/CABG
RCT,
valve
RCT,
CABG
RCT,
valve
RCT,
valve
RCT,
valve
RCT,
CABG
RCT,
CABG
RCT,
valve
RCT,
valve
RCT,
CABG
RCT,
CABG

Aminophylline (2)

Luo
(2004) [78]
Luo
(2007) [79]
Engel
(2009) [80]
Doddakula
(2010) [81]
Poulsen
(2009) [82]
Kipfer
(2003) [83]
Jimenez
(2011) [84]
El-Hamamsy
(2007) [85]
Mathew
(2009) [86]
Bennett-Guerrero
(2009) [87]
An
(2008) [88]
Huang
(2011) [89]
Kawamura
(2006) [90]
Cho
(2009) [91]
Gianetti
(2004) [92]
Colagrande
(2006) [93]
Lango
(2005) [94]
Koksal
(2008) [95]
Choi
(2010) [96]
Tamayo
(2008) [97]
Liu
(2009) [98]

Author (year)
[reference]8*

No

No

22
15

Yes: NE

28

15

21

33

14

Yes: ICU stay,
ventilation time
Yes: CK-MB,
cTnI
Yes: CK-MB,
TnT
No

No

No

No

No

No

No

No

No

Yes: ICU stay,
ventilator time
Yes: cTnI

Clinical Benefit
Yes–No:
Outcome Modified

No

No

No

Yes: soluble P-selectin Yes: CK-MB,
cTnI, BNP
Yes: IL-6, TNFa
Yes: ICU stay,
CK-MB, cTnI
Yes: lactate
Yes: endothelin,
oxidative stress
Yes: neutrophil count No

Yes: IL-6, IL-10

15

13

30

Yes: IL-8,
oxidative stress
Yes:IL-6, TNFa,
oxidative stress
Yes: IL-6, IL-8

No

15

49

No

No

50
114

No

No

No

Yes: IL-6

Yes: IL-8, IL-10,
TNFa
Yes: neutrophil
myeloperoxidase
Yes: IL-2, IFN-g, NE

80

15

22

15

31

15

15

No.9†

Inflammatory
Biomarker(S)
Suppressed Yes–No:
Biomarker10‡

Perioperative aminophylline infusion significantly improved
ventilator time and ICU length of stay
Significant myocardial protection (TnI); fewer neutrophils in
coronary sinus with less myeloperoxidase on biopsies
Infusion of glutamine after induction to postoperative day 3 did not
affect ventilation time, ICU stay, or organ dysfunction
Infusion of a 2% solution of the antioxidant agent taurine did not
affect hard clinical end points or ICU stay
2 + 500 IU/kg doses at days –1 and +1; no change in prespecified
clinical outcomes
Bleeding and transfusion benefits; no change in permitted
clinical outcomes
Double-dose TXA (40 + 40 mg/kg) versus single-dose control;
unwanted trend towards increased mortality and seizures
Intravenous infusion; concerning trend toward increased death
and MI; also trend toward myocardial injury (CK-MB and TnT)
Interaction of lidocaine with diabetes caused significant postoperative
cognitive decline
Infusion of ethyl pyruvate did not affect death, MI, ARF, or a raft
of clinical markers or hospital resource end points
Propofol targeted infusion during cross-clamp improved ventilation
time, lung compliance and ICU stay
Synergistic protective effect of isoflurane with propofol on ICU stay
and myocardial protection (CK-MB and TnI)
Fentanyl + sevoflurane anesthesia versus fentanyl + propofol control;
convincing myocardial protection (CK-MB and TnT)
Sevoflurane anesthesia versus fentanyl + midazolam control;
no change in ICU stay or other clinical end points
Continuous NO inhalation perioperatively and in ICU; protection
of myocardial injury markers (CK-MB, TnI, and BNP)
L-arginine (nitric oxide substrate) added to cardioplegia; convincing
improvement in ICU stay, CK-MB, and TnI
Diabetic cohort; propionyl L-carnitine in cardioplegia significantly
improved cardiac index, SVR, PVR, and lactate
Adenosine as an adjunct to cardioplegia did not improve clinical
end points or confer significant myocardial protection
Hydroxyethyl starch used as priming solution, versus albumin
control, did not affect ICU stay or inotrope use
Priming with gelatin colloid, versus crystalloid control, had no effect
on ventilation time, ICU stay, or need for inotropes
In cardioplegia; no change in hard clinical end points but same trend
as with intravenous infusion toward myocardial injury (CK-MB)

Comment

Number in square bracket refers to reference number in the Appendix B.
N = number of subjects in treatment group.
‡
Abbreviations used: RCT, randomized controlled trial; CABG, coronary artery bypass grafting; IL, interleukin; TNF, tumor necrosis factor; NE, neutrophil elastase; CRP, C-reactive protein;
A-a O2, arterial–alevolar oxygen gradient; CK-MB, creatine kinase MB fraction; cTn, cardiac-specific troponin; ICU, intensive care unit; STEMI, ST-elevation myocardial infarction.
§
N/D, not done.

†

*

N-acetyl cysteine (1)

Hydroxyethyl starch
in prime (1)
Gelatin colloid (1)

L-Arginine in
cardioplegia (1)
Propionyl
L-Carnitine (1)
Adenosine (1)

NO gas (1)

Isoflurane +
propofol (1)
Sevoflurane (2)

Propofol (1)

Ethylpyruvate (1)

Lidocaine (1)

Dual-dose
tranexamic acid (1)
N-acetyl cysteine (1)

Aprotinin (1)

Erythropoietin (1)

Taurine (1)

Glutamine (1)

Type of Study,
Surgery

Intervention
(no. of papers)

Table 5. Continued.
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Nitric Oxide: There were three RCTs examining different methods to deliver nitric oxide (NO) to patients
perioperatively: direct inhalation of NO gas, infusion of
sodium nitroprusside (NO donor), or L-arginine (NO substrate) added to cardioplegia. Taken together, these small
NO trials (median sample size n = 28) all demonstrated
clinical benefit.
Neutrophil Elastase Inhibitors: There were three RCTs
examining administration of neutrophil elastase inhibitors,
two of which used urinary protease inhibitor and one
human elastase inhibitor. Taken together, these small neutrophil elastase interventions (median sample size n = 30)
were adjudged clinically beneficial.
Propofol: There were two RCTs studying propofol
anesthesia. Both studies demonstrated a clinical outcome improvement. One study examined the interaction
between isoflurane preconditioning and propofol postconditioning and was able to demonstrate a clinical benefit
for this combination.
Aminophylline: There were two RCTs from the same
research group on the bronchodilator aminophylline. Both
of these small studies (n = 30) demonstrated a clinical benefit.
Sevoflurane: There were two RCTs on sevoflurane
anesthesia, only one of which demonstrated an improvement in a clinical outcome.
Intensive Insulin Therapy: There was one RCT on intensive insulin therapy using the Portland Protocol (22) in
patients with no history of diabetes. This well-designed study
(n = 100) showed a clinical benefit with significantly shortened intensive care unit stay and myocardial protection.
Fluvastatin: There was one RCT on fluvastatin administered for 3 weeks up to the day of surgery; this study
demonstrated clinical benefit.
Propionyl-L-Carnitine: There was one RCT on propionyl L-carnitine administration in a diabetic cohort
assigned a clinical benefit for this intervention.
Ultrafiltration: There were three RCTs on ultrafiltration using three different ultrafiltration techniques.
However, none of the trials recorded a significant depletion of inflammatory biomarkers and none achieved a
clinical benefit. There were no indications of negative
patient outcomes.
There was little evidence across the many varied interventions for causing harm, but lidocaine infusion exhibited
an interaction with diabetes leading to significantly worsened postoperative cognitive dysfunction. Two trials on
N-acetyl cysteine manifested a concerning trend for death
or myocardial injury in the treatment arm, whether
given intravenously or added to cardioplegia. Aspirin given
JECT. 2014;46:197–211

preoperatively was associated with worsened reoperative
rates. Finally, double-dose tranexamic acid revealed a
trend toward increased mortality and seizures.
Methodological Quality
Variable quality in methodological descriptions was
noted across the evidence base, particularly in areas of
blood management and the description of perfusion equipment used: 31.6% of papers provided inadequate or nonexistent protocols for blood management and 29.6% of
papers were classified as poor for equipment. Surgical
protocols were described more adequately with only 12.2%
of papers classified as poor in the evidence base.
Association between Inflammatory Suppression and
Clinical Benefit
The five most frequently monitored biomarkers for
inflammation (interleukin [IL]-6, IL-8, tumor necrosis factor a, neutrophil elastase and complement component C3a)
were also the five most often suppressed and most likely
to be associated with a clinical benefit. Suppression of
biomarkers occurred with similar frequency across the
three categories of intervention. It occurred in 68.4% of the
studies in surgical/perioperative management, 65.7% of
the studies of perfusion-related interventions, and 68.2%
of the investigations of pharmacological interventions.
DISCUSSION
The review strategy adopted in this systematic analysis,
combining self-identified anti-inflammatory studies with
inclusion criteria specified in the Outcomes consensus
statement (19), yielded a rich evidence base for antiinflammatory interventions covering surgical, pharmacological, and perfusion approaches. The overall clinical
dividend from this large body of literature yielded only
35.7% of papers capable of demonstrating a clinical benefit. The most widely studied intervention, steroid use,
showed no evidence for improvement of clinical outcomes
according to our analysis, which supports a recent
Cochrane review that concluded corticosteroids exerted
no clinical benefit on mortality, cardiac, or pulmonary
complications (21). On the positive side, there was little
evidence for harm associated with the many varied
attempts to inhibit the systemic inflammatory response
with only certain isolated interventions earning a precautionary negative recommendation (aspirin, lidocaine in
persons with diabetes, N-acetylcysteine, and double-dose
tranexamic acid).
Various surface coating and surface reduction strategies
showed some promise but no compelling clinical benefit,
including biocompatible surface coatings, minimized circuits, and off-pump coronary revascularization. The rationale for heparin coating, however, targeting factor IIa at
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the terminus of the coagulation cascade, must remain
questionable. It is likely that whatever clinical benefit heparin confers is the result of “part-time” inhibition higher
up the cascade at the level of factor IXa (23). We hypothesize that upstream interdictions might provide a better
opportunity for anti-inflammatory protection by blocking
the avalanche of activated factors at the top of the cascade.
On this basis, we highlight interventions using C1 esterase
inhibitor (Appendix B: references [69,70]), a pleiotropic
agent with upstream targets in coagulation, complement,
and fibrinolytic pathways (24). Both C1 esterase inhibitor
studies showed a clinical benefit in emergency CABG populations and both demonstrated a gradient effect with
improved myocardial protection associated with earlier
treatment from the point of acute ST-elevation myocardial
infarction. Other promising interventions such as NO therapy (Appendix B: references [77,92,93]) may also have
benefited from a pleiotropic mechanism of action, because
NO acts to promote vasodilation (25), has antiadhesive
effects on leukocytes (26), and anticoagulant properties
against platelets (27). We hypothesize that pleiotropic
agents like NO or C1 esterase inhibitor are able to achieve
a consistent clinical benefit by blocking multiple targets
in multiple pathways (13,28,29).
Filtration strategies to remove leukocytes or soluble
cytokines were not typically associated with any clinical
benefit. This contrasted with arterial line filters for removing microemboli, which earned a class I recommendation
in a previous evidence-based review (30). Some studies
noted exacerbation of leukocyte activation, presumably
as a result of adherence and activation of leukocytes at
the filter surface. Our observations are consistent with
the findings of other meta-analyses, which concluded that
leukocyte-depleting filters or zero-balanced ultrafiltration
did not confer significant clinical benefits (31,32).
The authors recognize some limitations to this critical
review. First, the review is not intended as a critical care
guide to manage patients after they have experienced a
severe systemic inflammatory response, but as a guide to
clinical practices aimed at limiting the inflammatory
response from the outset. We acknowledge that patient
distribution in the evidence base was highly skewed with
one Cochrane review on steroid use and one multicenter
trial on C5 inhibition accounting for over 60% of the total
number. We further recognize that a different “mix” of
papers was captured by our reviewing strategy compared
with other meta-analyses. For example, a previous metaanalysis on biocompatible surface coatings identified
36 papers, whereas only 14 qualified by our inclusion
criteria (33). This was attributable to the fact our search
was limited to a 10-year window and used more stringent
inclusion criteria. Nonetheless, we reached the same conclusion as that meta-analysis: that biocompatible surface
coatings without other measures to limit blood activation
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conferred only limited clinical benefit. In adopting the minimal reporting criteria of the consensus statement, we recognize that clinical benefit may be based on a single clinical
variable. Improvement of a single variable may not on its
own guarantee improvement in clinical outcome and benefits might best be accrued when treatments are used in
combination. Because few such combinations have been
evaluated systematically, this becomes an important area
for future research. The overall validity of our approach
was supported across several interventions with the current
review reaching similar conclusions as contemporary metaanalyses in the areas of: corticosteroid use, filtration, and
biocompatible surface coating (21,31–33). Regular updates
are warranted to capture changing practice and emerging
evidence outside the 10-year window of this review (34–36)
that may change clinical practice in the future.
The review highlighted several shortcomings in methodological quality. In addition to problems with small sample
size and heterogeneity of interventions and biomarkers
studied, there were fundamental shortcomings in methodological descriptions. This was particularly apparent for
blood management protocols and description of perfusion
equipment. Inadequate descriptions of these practices are
important, because they can impact inflammatory processes and clinical outcomes (30). We therefore advocate
the use of tables in the Methods section to itemize in detail
the system components of the bypass circuit and blood
management protocols used (37).
The broad scope of the current review yielded novel
insight into the relationship between anti-inflammatory
action and clinical efficacy. This arose from a secondary
analysis showing that 97% of papers with a clinical benefit
achieved suppression of at least one inflammatory marker
(Tables 3–5). However, over half the papers (57%) that did
not find a clinical benefit also did demonstrate suppression
of an inflammatory biomarker. This suggests that suppression of one inflammatory biomarker is therefore necessary
but not sufficient to translate into a clinical benefit.
CONCLUSIONS
This critical review concludes that no single intervention
used on its own demonstrates strong evidence for limiting
adverse outcomes as a result of the systemic inflammatory
response. A secondary analysis showed that suppression of
a single inflammatory biomarker was required but was not
sufficient to confer a clinical benefit. The most promising
interventions were those that targeted multiple inflammatory pathways. These results are consistent with a “multiple
hit” hypothesis, whereby clinically effective suppression of
the systemic inflammatory response requires hitting multiple inflammatory targets. Further research is warranted to
evaluate combinations of interventions capable of achieving
synergy by targeting the many pathways that are activated.
JECT. 2014;46:197–211
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